Overview

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension
Phase:
Phase 4
Details
Lead Sponsor:
Novartis